Abstract
Current limitations to on-demand drug manufacturing can be addressed by technologies that streamline manufacturing processes. Combining the production of two or more drugs into a single batch could not only be useful for research, clinical studies, and urgent therapies but also effective when combination therapies are needed or where resources are scarce. Here we propose strategies to concurrently produce multiple biologics from yeast in single batches by multiplexing strain development, cell culture, separation, and purification. We demonstrate proof-of-concept for three biologics co-production strategies: (i) inducible expression of multiple biologics and control over the ratio between biologic drugs produced together; (ii) consolidated bioprocessing; and (iii) co-expression and co-purification of a mixture of two monoclonal antibodies. We then use these basic strategies to produce drug mixtures as well as to separate drugs. These strategies offer a diverse array of options for on-demand, flexible, low-cost, and decentralized biomanufacturing applications without the need for specialized equipment.
Introduction
Traditional biologics manufacturing follows a rigid "one drug, one facility" model. Producing a single protein—such as insulin or a monoclonal antibody—requires dedicated cell lines, massive bioreactors, and complex purification pipelines. This centralized approach is slow, expensive, and vulnerable to supply chain disruptions. Furthermore, producing combination therapies (drug cocktails) is economically challenging because each component must typically be manufactured and purified independently.
To address these challenges, this research introduces a versatile yeast-based platform capable of producing multiple biological drugs simultaneously in a single batch. By engineering Pichia pastoris with orthogonal inducible promoters and co-culture strategies, the researchers demonstrate a flexible, low-cost approach to manufacturing drug mixtures and stabilizers on-demand, potentially revolutionizing decentralized biomanufacturing.
Methods
The researchers utilized the yeast Pichia pastoris as a production host due to its rapid growth, high protein secretion capacity, and eukaryotic machinery for proper protein folding. The study employed a library of engineered strains carrying various therapeutic payloads, including human growth hormone (hGH), Interferon α-2b (IFNα-2b), human serum albumin (HSA), and monoclonal antibodies (anti-PD1/anti-CTLA4).
Orthogonal Inducible Systems A key innovation is the implementation of three distinct genetic "switches" that respond to different chemical triggers: Methanol, Estrogen, and a newly engineered IPTG-inducible system. This allows for the independent control of specific gene expressions within the same cell, enabling precise tuning of drug ratios.
Consolidated Bioprocessing To produce a drug alongside a stabilizer (e.g., hGH and HSA), the team engineered a fusion protein. They localized a specific protease (TEV) to the yeast's Golgi apparatus to "clip" the fusion into separate functional proteins just before secretion, effectively turning the cell’s internal membrane system into an assembly line.
Co-culture and Co-purification For complex mixtures like monoclonal antibody (mAb) cocktails, specialized yeast strains were grown in the same batch. The final mixture was then purified using a single-step affinity chromatography process.
Key Results
The platform demonstrated significant versatility and efficiency across several metrics:
- High Yields: The system achieved titers of 189 mg/L for hGH and 53 mg/L for IFNα-2b when co-produced. Interestingly, co-expression actually increased the yield of hGH compared to producing it alone.
- Effective Separation: Using a simple two-stage salt gradient on a single Blue Sepharose column, the team recovered 92.4% pure hGH and 95.4% pure HSA from a mixed supernatant.
- Functional Antibodies: Yeast-produced anti-PD1 and anti-CTLA4 antibodies showed binding affinities and checkpoint inhibitory activity equivalent to commercial standards, validated through human primary T-cell assays.
- Orthogonality: The three-way induction system showed virtually no cross-talk, allowing independent control of three different therapeutic proteins in one culture.
Discussion and Limitations
The ability to adjust drug ratios "on-the-fly" by changing inducer concentrations offers a level of dynamic control not possible with traditional co-cultures. However, several challenges remain for field deployment. The current system relies on inducers like methanol and estrogen which require specific storage conditions; future versions might utilize more stable chemical or optogenetic (light-based) triggers. Additionally, while Pichia is a eukaryotic host, its glycosylation patterns are not identical to humans, necessitating further work with "humanized" yeast strains.
Ultimately, this proof-of-concept at the benchtop scale paves the way for integrating programmable yeast into portable, automated microbioreactors, enabling true point-of-care manufacturing in remote or resource-poor environments.
Summary updated